Want to see BBIO full AI Analyst Report?
BBIO Stock Chart & Stats
$84.02
$1.09(1.31%)
At close: 4:00 PM EDT
$84.02
$1.09(1.31%)
Day’s Range― - ―
52-Week Range$42.09 - $93.42
Previous CloseN/A
Volume2.06M
Average Volume (3M)4.02M
Market Cap
$16.38B
Enterprise Value$16.92K
Total Cash (Recent Filing)$940.19M
Total Debt (Recent Filing)$3.38B
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.75
Shares Outstanding196,036,790
10 Day Avg. Volume2,133,765
30 Day Avg. Volume4,019,845
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)-7.27
Price to Sales (P/S)30.05
P/FCF Ratio-33.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$107.39Price Target Upside27.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)-2.25
Revenue Forecast (FY)$961.37M
Bulls Say, Bears Say
Bulls Say
Rapid Atruvio Revenue GrowthSustained, large QoQ and YoY Atruvio growth demonstrates durable commercial traction and expanding patient uptake. This revenue base can fund scale, enable operating leverage as fixed costs are spread, and underpins management's path to breakeven while supporting launches of additional pipeline assets.
Very High Gross Margins (~95%)A ~95% gross margin signals strong unit economics for product sales in ATTR and related specialty medicines. High gross margins create a durable buffer to absorb SG&A and R&D spending, improving the company’s ability to translate higher sales into operating leverage and eventual profitability over time.
Strengthened Capital Runway Via FinancingThe large preferred equity raise materially improves liquidity and reduces near-term refinancing risk, providing permanent capital to fund commercialization and multiple planned launches. This structural funding supports execution of the commercial strategy and lowers the immediacy of dilution from near-term equity raises.
Bears Say
Large Ongoing Cash Burn And Negative FCFPersistent negative operating and free cash flow indicate the business remains cash‑consumptive absent sustained commercial scale. Continued burn elevates dependency on external financing, risks dilution, and constrains discretionary investment if revenues slow or launch costs run higher than planned.
Negative Stockholders' EquityA sizable negative equity balance reflects accumulated losses and weak capital buffer, reducing financial flexibility. Over time this increases refinancing and covenant risk, may limit partner or payer confidence, and can force suboptimal financing choices if operational performance falters.
Revenue Concentrated In One ProductHeavy dependence on a single commercial product concentrates execution and access risk: payer decisions, diagnostic bottlenecks, or competitive entrants could materially affect revenues. Durable risk remains until additional pipeline approvals and launches materially diversify the revenue base.
BridgeBio Pharma News
BBIO FAQ
What was Bridgebio Pharma’s price range in the past 12 months?
Bridgebio Pharma lowest stock price was $42.09 and its highest was $93.42 in the past 12 months.
What is Bridgebio Pharma’s market cap?
Bridgebio Pharma’s market cap is $16.38B.
When is Bridgebio Pharma’s upcoming earnings report date?
Bridgebio Pharma’s upcoming earnings report date is Oct 29, 2026 which is in 90 days.
How were Bridgebio Pharma’s earnings last quarter?
Currently, no data Available
Is Bridgebio Pharma overvalued?
According to Wall Street analysts Bridgebio Pharma’s price is currently Undervalued.
Does Bridgebio Pharma pay dividends?
Bridgebio Pharma does not currently pay dividends.
What is Bridgebio Pharma’s EPS estimate?
Bridgebio Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bridgebio Pharma have?
Bridgebio Pharma has 196,036,790 shares outstanding.
What happened to Bridgebio Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bridgebio Pharma?
Currently, no hedge funds are holding shares in BBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BridgeBio Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$107.39 (27.81% Upside)
$107.39 (27.81% Upside)
Blogger Sentiment
Neutral
BBIO Sentiment 50%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 2.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
84.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
55.50%
Trailing 12-Months
Company Description
Bridgebio Pharma
BridgeBio Pharma, Inc. (BBIO) is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for genetic diseases and cancers. The company operates through a portfolio model, advancing multiple drug programs spanning early research through late-stage clinical development and commercialization, with its lead commercial product being ATTR amyloidosis therapy acoramidis (marketed as Attruby in the U.S.).
BBIO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum (notably Atruvio revenue growth: $180.6M, +24% QoQ, +392% YoY), robust cash runway ($940.2M) and clear pipeline progress with active launch preparations (LGMD2I NDA, ADH1 patient ID, positive PROPEL‑3 for achondroplasia). Management emphasized clinical differentiation backed by real‑world evidence and favorable long‑term economics, while acknowledging short‑term expense pressures (operating expenses +$72.1M) and an operating loss of $106M that should narrow later in the year. Competitive risks, diagnostic supply issues, and the prior‑year milestone timing created some near‑term revenue volatility, but overall the company presented multiple tangible positives that outweigh the listed challenges.View all BBIO earnings summariesBBIO Stock 12 Month Forecast
Average Price Target
$107.39
▲(27.81% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Ionis Pharmaceuticals
―
Madrigal Pharmaceuticals
―
Moderna
―
Ownership Overview
3.95% Insiders
26.93% Mutual Funds
0.54% Other Institutional Investors
55.86% Public Companies and
Individual Investors